News
13h
News-Medical.Net on MSNStudy provides a molecular snapshot of Tanshi constitution's immunological landscapeThe study aims to uncover the immunological basis of Tanshi (phlegm-dampness) constitution—a subhealth type in traditional ...
Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clinical Cancer Research , 2023 ...
Follicular dendritic cell sarcoma in the right chest wall Hongli X and others Medicine (Baltimore), 2020. Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic ...
In a subgroup analysis of the 176-patient trial, however, progression-free survival was significantly better with the dendritic cell therapy in patients with non-epithelioid histology (5.7 vs 2.9 ...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a type of blood cancer that affects immune system cells. It most often affects the skin but can also involve bone marrow and other cell types.
Diakonos Oncology’s dendritic cell immunotherapy previously received Fast Track designation for glioblastoma multiforme. Results from a phase 1 trial (ClinicalTrials.gov Identifier: ...
The study aims to uncover the immunological basis of Tanshi (phlegm-dampness) constitution—a subhealth type in traditional Chinese medicine ...
Scientists have pinpointed a crucial network of immune cells that allows humans to digest food safely without triggering ...
A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk ...
Dubodencel, also known as DOC1021, is a first-in-class, double-loaded autologous dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA.
Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results